For a startup founded last year last year, Vir Biotechnology has a lot going for it. At its helm is George Scangos, the former Biogen CEO. It has $500 million from investors — including very early investments from the Bill and Melinda Gates Foundation — and a pipeline with dozens of potential drugs.

Now, it has its first clinical trial: a drug for hepatitis B. The company announced Monday that it had begun dosing in a Phase 1 trial for its drug based on the gene-silencing technology known as RNA interference, or RNAi.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy